Next Article in Journal
Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model
Next Article in Special Issue
Role of microRNAs in Hemophilia and Thrombosis in Humans
Previous Article in Journal
A Novel Protocol for Detection of Senescence and Calcification Markers by Fluorescence Microscopy
Previous Article in Special Issue
Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition
Review

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

by 1, 2 and 1,*
1
TAmiRNA GmbH, 1110 Vienna, Austria
2
King’s British Heart Foundation Centre, King’s College London, London SE5 9NU, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(10), 3477; https://doi.org/10.3390/ijms21103477
Received: 3 April 2020 / Revised: 8 May 2020 / Accepted: 11 May 2020 / Published: 14 May 2020
(This article belongs to the Special Issue MicroRNAs as Biomarkers and Effector Molecules of Thrombosis)
Given the high morbidity and mortality of cardiovascular diseases (CVDs), novel biomarkers for platelet reactivity are urgently needed. Ischemic events in CVDs are causally linked to platelets, small anucleate cells important for hemostasis. The major side-effect of antiplatelet therapy are life-threatening bleeding events. Current platelet function tests are not sufficient in guiding treatment decisions. Platelets host a broad spectrum of microRNAs (miRNAs) and are a major source of cell-free miRNAs in the blood stream. Platelet-related miRNAs have been suggested as biomarkers of platelet activation and assessment of antiplatelet therapy responsiveness. Platelets release miRNAs upon activation, possibly leading to alterations of plasma miRNA levels in conjunction with CVD or inadequate platelet inhibition. Unlike current platelet function tests, which measure platelet activation ex vivo, signatures of platelet-related miRNAs potentially enable the assessment of in vivo platelet reactivity. Evidence suggests that some miRNAs are responsive to platelet inhibition, making them promising biomarker candidates. In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. We also elaborate on technical issues and limitations concerning plasma miRNA quantification. View Full-Text
Keywords: microRNA; platelets; biomarker; antiplatelet therapy; platelet activation; circulating microRNAs; platelet microvesicles; platelet-related miRNA microRNA; platelets; biomarker; antiplatelet therapy; platelet activation; circulating microRNAs; platelet microvesicles; platelet-related miRNA
Show Figures

Figure 1

MDPI and ACS Style

Krammer, T.L.; Mayr, M.; Hackl, M. microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring. Int. J. Mol. Sci. 2020, 21, 3477. https://doi.org/10.3390/ijms21103477

AMA Style

Krammer TL, Mayr M, Hackl M. microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring. International Journal of Molecular Sciences. 2020; 21(10):3477. https://doi.org/10.3390/ijms21103477

Chicago/Turabian Style

Krammer, Teresa L., Manuel Mayr, and Matthias Hackl. 2020. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring" International Journal of Molecular Sciences 21, no. 10: 3477. https://doi.org/10.3390/ijms21103477

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop